Flu-Bu-Mel Based Conditioning Regimen for Patients With Lymphoid Malignancies Undergoing Allo-HSCT

• Status: Recruiting
• Trial end date: 2024-01-01
• Target enrollment: 0
• Participant gender: All

Summary

In this phase II clinical trial, we evaluate the efficacy and feasibility of conditioning regimen of fludarabine 150mg/m2, busulfan 9.6mg/kg, melphalan 100mg/m2 and etoposide 800mg/m2 in patients with lymphoid malignancies.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai Jiao Tong University School of Medicine

Criteria

Inclusion Criteria:

• lymphoid malignancies

• donor available: HLA matched sibling, unrelated donor or haplo-identical related donor.

• patients with ECOG <3

Exclusion Criteria:

• inform consent not provided

• ECOG >=3

• poor liver function (enzyme >2N or bilirubin >2N)

• poor renal function (Scr >2N)

• poor cardiac function (EF <45%)